This is an aggregated industry headline. Read the full story at BioPharma Dive →
A new Westlake-backed biotech takes aim at migraines
Vedana Therapeutics emerged from stealth Wednesday with $46 million to support its mission of developing "anti-PACAP" therapies, an increasingly popular strategy for migraine prevention.
By BioPharma Dive
· Jun 17, 2026
· via BioPharma Dive
Image: BioPharma Dive
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
With pharma and life sciences deal values surpassing $65 billion in the first quarter, marking the strongest q…
The WeekFierceBiotech ↗
With a panel of outside experts set to weigh in Thursday-and with a refusal-to-file fiasco with the FDA just b…
The WeekBriefing
Starting next month, Medicare will offer weight loss drug coverage through a temporary program that observers …